Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

Nature·2026
Same author

INST'AJA: a co-designed Instagram campaign to promote sexual health education and behaviors in adolescent and young adult cancer survivors.

The journal of sexual medicine·2026
Same author

Translating ctDNA into cutaneous melanoma care: An international expert survey.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities.

Molecular oncology·2025
Same author

Perspectives on Artificial Intelligence in Medical Publishing: A Survey of Medical Journal Editors.

Journal of cardiovascular pharmacology·2025
Same author

Approaches to overcome the current treatment plateau in immunotherapy.

European journal of cancer (Oxford, England : 1990)·2025

Related Experiment Video

Updated: May 3, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

12.9K

Trial Watch: Lenalidomide-based immunochemotherapy.

Michaela Semeraro1, Erika Vacchelli2, Alexander Eggermont3

  • 1Gustave Roussy; Villejuif, France ; INSERM, U1015, CICBT507; Villejuif, France.

Oncoimmunology
|February 1, 2014
PubMed
Summary
This summary is machine-generated.

Lenalidomide, a thalidomide derivative, shows direct anti-cancer effects and boosts the immune system. Clinical trials are exploring its efficacy in various hematological and solid malignancies.

Keywords:
CC-5013IMiDsTNFαchronic lymphocytic leukemiapomalidomideregulatory T cells

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

20.8K

Related Experiment Videos

Last Updated: May 3, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

12.9K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

20.8K

Area of Science:

  • Immunology
  • Pharmacology
  • Oncology

Background:

  • Lenalidomide is an FDA-approved drug for multiple myeloma and specific myelodysplastic syndromes.
  • Its mechanism involves direct anti-cancer effects and modulation of the tumor microenvironment.

Approach:

  • Reviewing studies on lenalidomide's antineoplastic and immunostimulatory potential.
  • Analyzing current clinical trials for safety and efficacy in oncological indications.

Key Points:

  • Lenalidomide has direct cell cycle-arresting and pro-apoptotic effects on cancer cells.
  • It stimulates cytotoxic immune cells (T lymphocytes, NK cells) and modulates cytokine profiles.
  • Lenalidomide limits the immunosuppressive effects of regulatory T cells.

Conclusions:

  • Lenalidomide exhibits multifaceted anti-cancer activity through direct and immunomodulatory mechanisms.
  • Ongoing research investigates its broader application in treating diverse hematological and solid tumors.